L26/P-051 Role of hormone therapy in infertile men with severe oligoasthenozoospermia and non-obstructive azoospermia according to the APHRODITE criteria: a prospective cohort study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.387 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Dasgupta und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does hormone therapy guided by APHRODITE criteria improve ejaculated sperm parameters and surgical sperm retrieval rates? Does it enhance chances of natural or assisted conception? Summary answer Hormone therapy improved ejaculated sperm parameters and reduced the need for surgical sperm retrieval; effects on natural or assisted conception remain inconclusive. What is known already Except for hypogonadotropic hypogonadism, the role of hormone therapy in normogonadotropic and hypergonadotropic male infertility remains controversial, despite reports of potential benefits in selected patients. The APHRODITE (Addressing Male Patients With Hypogonadism and/or Infertility Owing to Altered, Idiopathic Testicular Function) classification stratifies infertile men using semen analysis and hormonal profiles to support biologically guided research and treatment strategies. However, prospective studies evaluating whether hormone therapy improves sperm parameters and reproductive outcomes—either naturally or following intracytoplasmic sperm injection (ICSI)—in men with severe oligoasthenozoospermia or non-obstructive azoospermia (NOA) across APHRODITE groups are lacking. Study design, size, duration This prospective cohort study was conducted at a tertiary fertility centre between May 2024 and October 2025, following Institutional Ethics Committee approval and written informed consent. Among 419 men with severe oligoasthenozoospermia (total motile sperm count [TMSC] <5 million) or NOA, 354 with idiopathic aetiology were eligible for hormone therapy according to APHRODITE groups 1–4. Of these, 201 accepted treatment and 153 declined. Participants/materials, setting, methods Eligible men received human chorionic gonadotrophin and/or follicle-stimulating hormone according to APHRODITE classification. Semen analyses were repeated every three months, with cryopreservation when feasible. In men with severe oligoasthenozoospermia, treatment continuation and ART recommendations were guided by TMSC. In NOA, the appearance of sperm in the ejaculate was assessed. Multivariable logistic regression models adjusted for relevant confounders were used. Odds ratio (OR), 95% confidence interval (95% CI) and P-value were calculated. Main results and the role of chance Overall, hormone therapy was associated with a significant improvement in sperm parameters compared with no treatment (OR 2.45, 95% CI 1.50–3.90; P < 0.001), after adjustment for age, body mass index, smoking status, testicular volume, and baseline hormone levels. Similar improvements were observed across APHRODITE groups 2–4; all men in group 1 received treatment. In men with NOA, sperm appeared in the ejaculate more frequently following hormone therapy, thereby avoiding surgical sperm retrieval (OR 4.00, 95% CI 1.78–8.99; P = 0.001). Among men with severe oligoasthenozoospermia, hormone therapy significantly increased the likelihood of achieving TMSC ≥5 million (OR 5.75, 95% CI 2.58–12.83; P < 0.001). Reproductive outcomes were analysed descriptively. Hormone therapy was not associated with statistically significant differences in natural conception, ICSI outcomes, or overall pregnancy rates; however, the study was not powered for these endpoints, follow-up was incomplete, and several pregnancies were ongoing at study closure. Limitations, reasons for caution This was a non-randomized, single-centre study. The sample size and follow-up duration were insufficient to reliably assess reproductive outcomes, and results may not be generalisable to other populations. Wider implications of the findings Hormone therapy may improve spermatogenic output and reduce the need for surgical sperm retrieval in selected men with severe oligoasthenozoospermia or NOA. Its impact on natural and assisted conception requires confirmation in adequately powered studies with longer follow-up. Trial registration number No
Zitieren
APA
Dasgupta, S., Banerjee, M., Chanda, A., & Esteves, S. (2026). L26/P-051 Role of hormone therapy in infertile men with severe oligoasthenozoospermia and non-obstructive azoospermia according to the APHRODITE criteria: a prospective cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.387
Vancouver
Dasgupta S, Banerjee M, Chanda A, Esteves S. L26/P-051 Role of hormone therapy in infertile men with severe oligoasthenozoospermia and non-obstructive azoospermia according to the APHRODITE criteria: a prospective cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.387
BibTeX
@article{Dasgupta2026,
author = {Dasgupta, S. and Banerjee, M. and Chanda, A. and Esteves, S.C.},
title = {L26/P-051 Role of hormone therapy in infertile men with severe oligoasthenozoospermia and non-obstructive azoospermia according to the APHRODITE criteria: a prospective cohort study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.387}
}
EUVIMED